CLAIMS

What is claimed is:

1. A ~~method~~ composition for treating hidradenitis suppurtiva in a subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject in need thereof ~~a JAK inhibitor selected from the group consisting of JAK1, Tyk2/JAK1, and Tyk2.~~

~~2. The method of claim 1, wherein said Tyk2/JAK1 inhibitor is~~ [(1S)-2,2-difluorocyclo-propyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone; or, a pharmaceutically acceptable salt thereof.

~~3. The method of claim 1, wherein said Tyk2/JAK1 inhibitor is [(1R)-2,2-difluorocyclo-propyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone; or, a pharmaceutically acceptable salt thereof.~~

~~4~~2. The method of claim ~~3~~1, wherein said salt is the *p*-toluenesulfonic acid salt.

~~5. The method of claim 1, wherein said JAK1 inhibitor is N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-propane-1-sulfonamide, or a pharmaceutically acceptable salt thereof.~~

~~6. The method of claim 1, wherein said Tyk2 inhibitor is (1r,3r)-3-(cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile, or a pharmaceutically acceptable salt thereof.~~

~~7. The method of claim 1, wherein said Tyk2 inhibitor is (1s,3s)-3-(cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile, or a pharmaceutically acceptable salt thereof.~~

~~8~~3. The ~~method~~ composition~~method~~ of claims 1 ~~to 7~~or 2, wherein the treatment reduces inflammatory nodules, abscess and draining fituals as measured by the subject's HiSCR score .

~~9~~4. The ~~method~~ composition~~method~~ of claims 1 ~~to 7~~or 2, wherein the treatment reduces the median size of the subject's hidradenitis suppurativa lesions.

~~10~~5. The ~~method~~ composition~~method~~ of claims 1 ~~to 7~~or 2, wherein the treatment reduces the subject's pain associated with the subject's hidradenitis suppurativa lesions.

~~11~~6. The ~~method~~ composition~~method~~ of claims 1 ~~to 7~~or 2, wherein the treatment increases the subject's time to develop new hidradenitis suppurativa lesions.

~~12~~7. A ~~method~~ composition~~method~~ for treating hidradenitis suppurtiva in a human subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject in need thereof [(1S)-2,2-difluorocyclo-propyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone; or, a pharmaceutically acceptable salt thereof~~a JAK inhibitor selected from the group consisting of JAK1, Tyk2/JAK1 or Tyk2 in an amount effective to treat a symptom of hidradenitis suppurativa in the subject~~.

~~13~~8. The ~~method~~ composition~~method~~ of claim ~~12~~7, wherein said effective amount is about 0.01 to about 100 mg/kg of body weight/day, in a single dose or as divided doses administered two, three or four times per day.

~~14. A method for treating hidradenitis suppurtiva in a human subject having lesions associated with hidradenitis suppurativa, the method comprising the step of administering to the subject in need thereof N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-propane-1-sulfonamide, or a pharmaceutically acceptable salt thereof, in an amount effective to treat a symptom of hidradenitis suppurativa in the subject.~~

~~15. (Original) The method of claim 14, wherein said effective amount is about 0.01 to about 100 mg/kg of body weight/day, in a single dose or as divided doses administered two, three or four times per day.~~